Compare MDXH & IRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MDXH | IRIX |
|---|---|---|
| Founded | 2003 | 1989 |
| Country | Belgium | United States |
| Employees | 364 | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0M | 12.6M |
| IPO Year | 2021 | 1996 |
| Metric | MDXH | IRIX |
|---|---|---|
| Price | $0.16 | $0.66 |
| Analyst Decision | Hold | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $0.83 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 84.2K |
| Earning Date | 11-12-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,593,000.00 |
| Revenue This Year | $6.81 | N/A |
| Revenue Next Year | $13.37 | $6.58 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.15 | $0.61 |
| 52 Week High | $4.63 | $1.65 |
| Indicator | MDXH | IRIX |
|---|---|---|
| Relative Strength Index (RSI) | 22.87 | 43.48 |
| Support Level | N/A | $0.70 |
| Resistance Level | $0.64 | $1.00 |
| Average True Range (ATR) | 0.02 | 0.04 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 9.87 | 12.86 |
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.